Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls (Q29994559)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

8 April 2021

Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

immunization programs

1 reference

8 April 2021

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Michelle J. Groome

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Kate O'Brien

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Peter G. Smith

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

11

Shabir A Madhi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

John Anthony Gerard Scott

18 March 2020

18

object named as

J Anthony Scott

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

23

Cynthia G Whitney

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

25

Elizabeth R Zell

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

21

Jacqueline E Tate

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

14

Umesh D Parashar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

9

Rana A Hajjeh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

3

Claire V Broome

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

16

Laura C Rodrigues

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1

Jennifer R Verani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

2

Abdullah H Baqui

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

4

Thomas Cherian

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

6

Jennifer L Farrar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

12

Kim Mulholland

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

7

Daniel R Feikin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

20

Halvor Sommerfelt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

10

Hope L Johnson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Manish M Patel

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

J Chris Victor

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Anita K Zaidi

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Mathuram Santosham

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

language of work or name

English

0 references

publication date

22 April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

5 June 2017

1 reference

8 April 2021

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

8 April 2021

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

3295-3302

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International

18 March 2020

copyright license

1 reference

Placebo use in vaccine trials: recommendations of a WHO expert panel

8 April 2021

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Assessing vaccine efficacy in the field. Further observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Vaccine effects and impact of vaccination programmes in post-licensure studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Herd immunity: history, theory, practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Use of the case-control approach in vaccine evaluation: efficacy and adverse effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Retrospective assessment of the effectiveness of BCG vaccination against tuberculosis using the case-control method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Estimation of vaccine effectiveness using the screening method.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of Haemophilus influenzae type b vaccination against bacterial pneumonia in Colombia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of Haemophilus influenzae type B conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Haemophilus influenzae type b conjugate vaccine impact against purulent meningitis in Rwanda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Haemophilus influenzae type b conjugate vaccine is highly effective in the Ugandan routine immunization program: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Action for child survival: elimination of Haemophilus influenzae type b meningitis in Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Impact of Haemophilus influenzae type b conjugate vaccine on bacterial meningitis in the Dominican Republic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of haemophilus influenzae type B conjugate vaccine for prevention of meningitis in Senegal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Evaluation of the effectiveness of Haemophilus influenzae type b conjugate vaccine introduction against radiologically-confirmed hospitalized pneumonia in young children in Ukraine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of Haemophilus influenzae type b conjugate vaccine on radiologically-confirmed pneumonia in young children in Pakistan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of the 7-valent pneumococcal conjugate vaccine against vaccine-type invasive disease among children in Uruguay: an evaluation using existing data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in south africa: a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of pneumococcal conjugate vaccine against presumed bacterial pneumonia hospitalisation in HIV-uninfected South African children: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Vaccines for preventing influenza in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Fulfilling the promise of rotavirus vaccines: how far have we come since licensure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of Monovalent Rotavirus Vaccine (Rotarix) against Severe Diarrhea Caused by Serotypically Unrelated G2P[4] Strains in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of monovalent and pentavalent rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of the Monovalent G1P[8] Human Rotavirus Vaccine Against Hospitalization for Severe G2P[4] Rotavirus Gastroenteritis in Belém, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of rotavirus vaccines for prevention of rotavirus gastroenteritis-associated hospitalizations in Israel: a case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Duration of protection of pentavalent rotavirus vaccination in Nicaragua

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Case-Control Evaluation of the Effectiveness of the G1P[8] Human Rotavirus Vaccine during an Outbreak of Rotavirus G2P[4] Infection in Central Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of pentavalent rotavirus vaccine against severe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of rotavirus vaccine against hospitalized rotavirus diarrhea: A case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of mass oral cholera vaccination in Beira, Mozambique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Use of oral cholera vaccines in an outbreak in Vietnam: a case control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Use of Vibrio cholerae vaccine in an outbreak in Guinea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Bias in case-control studies. A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Statistical power in COVID-19 case-control host genomic study design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

World Health Organisation definition of "radiologically-confirmed pneumonia" may under-estimate the true public health value of conjugate pneumococcal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Putting surveillance data into context: the role of health care utilization surveys in understanding population burden of pneumonia in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Health care utilization and symptom severity in Ghanaian children--a cross-sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Health care-seeking behavior during childhood diarrheal illness: results of health care utilization and attitudes surveys of caretakers in western Kenya, 2007-2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Obtaining power or obtaining precision. Delineating methods of sample-size planning.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Methodology and measurement of the effectiveness of Haemophilus influenzae type b vaccine: systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Compared to what? Finding controls for case-control studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Selection of controls in case-control studies. I. Principles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Selection of controls in case-control studies. II. Types of controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Selection bias: neighbourhood controls and controls selected from those presenting to a Health Unit in a case control study of efficacy of BCG revaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

The test-negative design for estimating influenza vaccine effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

The case test-negative design for studies of the effectiveness of influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: An analysis using the indirect cohort method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Serotype replacement in disease after pneumococcal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Potential effect of virus interference on influenza vaccine effectiveness estimates in test-negative designs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Why match? Investigating matched case-control study designs with causal effect estimation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

The introduction of new vaccines into developing countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.037

Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada

7 January 2021

1 reference

12 December 2020

Evaluating new vaccines for developing countries. Efficacy or effectiveness?

1 reference

12 December 2020

The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials

1 reference

12 December 2020

Field evaluation of vaccine efficacy

1 reference

12 December 2020

Measuring protection: efficacy versus effectiveness.

1 reference

12 December 2020

10.1016/J.VACCINE.2017.04.037

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28442231%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

PubMed publication ID

28442231

1 reference